Inmune Bio, Inc. (INMB) › Operating IncomeInmune Bio, Inc. (INMB) — Operating IncomeAnnual figures by period end, from SEC filings.2017-12-31: -$981.5K2018-12-31: -$12.44M2019-12-31: -$7.76M2020-12-31: -$12.23M2021-12-31: -$29.15M2022-12-31: -$25.95M2023-12-31: -$29.74M2024-12-31: -$42.63M2025-12-31: -$47.38M-$47.38M2017-12-31Operating Income (USD)2025-12-31Period endedOperating IncomeChange YoYSource filing2025-12-31-$47.38M—2026-03-30From 2025-01-012024-12-31-$42.63M—2026-03-30From 2024-01-012023-12-31-$29.74M—2025-03-27From 2023-01-012022-12-31-$25.95M—2024-03-28From 2022-01-012021-12-31-$29.15M—2023-03-02From 2021-01-012020-12-31-$12.23M—2022-03-03From 2020-01-012019-12-31-$7.76M—2021-03-04From 2019-01-012018-12-31-$12.44M—2020-03-11From 2018-01-012017-12-31-$981.5K—2019-03-29From 2017-01-01Other metrics: RevenueCost of RevenueGross ProfitNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)